TABLE 2.
Incidence and time to AmB-induced AKI according to different definitions, stratified by type of AmB preparationa
| Patient group | No. of patients with AKI/total no. tested (%) by: |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Binary criteria |
KDIGO stage |
Time to AKI (days) by the following criterion: |
|||||||
| NT2× | NT0.5 | KDIGObin | Stage 1 | Stage 2 | Stage 3 | NT2× | NT0.5 | KDIGObin | |
| All (n = 24) | 4/24 (16.7) | 15/24 (62.5) | 17/24 (70.8) | 13/24 (54.2) | 4/24 (16.7) | 0/24 (0.0) | 10.3 ± 3.4 (n = 4) | 8.0 ± 3.4 (n = 15) | 7.2 ± 3.1 (n = 17) |
| Deoxycholate AmB (n = 12) | 3/12 (25.0) | 9/12 (75.0) | 10/12 (83.3) | 7/12 (58.3) | 3/12 (25.0) | 0/12 (0.0) | 9.3 ± 3.5 (n = 3) | 7.3 ± 3.5 (n = 9) | 7.1 ± 3.6 (n = 10) |
| Liposomal AmB (n = 12) | 1/12 (8.3) | 6/12 (50.0) | 7/12 (58.3) | 6/12 (50.0) | 1/12 (8.3) | 0/12 (0.0) | 13.0 (n = 1) | 9.0 ± 3.4 (n = 6) | 7.3 ± 2.6 (n = 7) |
Continuous data are expressed as means ± standard deviations. AmB, amphotericin B; NT2×, traditional nephrotoxicity criterion that requires at least doubling of the SCr level; NT0.5, traditional nephrotoxicity criterion that requires an absolute increase in the SCr level of at least 0.5 mg/dl; KDIGObin, Kidney Disease: Improving Global Outcomes criterion that requires an increase in the SCr level by ≥0.3 mg/dl within 48 h or an increase in the SCr level to ≥1.5 times the baseline level which is known or presumed to have occurred within the prior 7 days. KDIGO stage 1 required an increase in the SCr level by ≥0.3 mg/dl or to a level 1.5 to 1.9 times the baseline level; stage 2 required an increase in the SCr levels to 2.0 to 2.9 times the baseline level, and stage 3 required an increase in the SCr level to a level ≥3.0 times the baseline level or initiation of dialysis.